CoChat

Cross-Sectional Analysis of Baseline Visual Parameters in Subjects Recruited Into the RESCUE and REVERSE ND4-LHON Gene Therapy Studies

Open access

The DOI matches its Crossref record; 29 of the 30 references it cites were found in a registry or an index; none of the 3 sources its claims cite is checked for support yet.

Abstract

Objective: This report presents a cross-sectional analysis of the baseline characteristics of subjects with Leber hereditary optic neuropathy enrolled in the gene therapy trials RESCUE and REVERSE, to illustrate the evolution of visual parameters over the first year after vision loss. Methods: RESCUE and REVERSE were 2 phase III clinical trials designed to assess the efficacy of rAAV2/2-ND4 gene therapy in ND4-LHON subjects. At enrollment, subjects had vision loss for ≤6 months in RESCUE, and between 6 and 12 months in REVERSE. Functional visual parameters (best-corrected visual acuity [BCVA], contrast sensitivity [CS], and Humphrey Visual Field [HVF]) and structural parameters assessed by spectral-domain optical coherence tomography were analyzed in both cohorts before treatment. The cross-sectional analysis of functional and anatomic parameters included the baseline values collected in all eyes at 2 different visits (Screening and Inclusion). Results: Seventy-six subjects were included in total, 39 in RESCUE and 37 in REVERSE. Mean BCVA was significantly worse in RESCUE subjects compared with REVERSE subjects (1.29 and 1.61 LogMAR respectively, P = 0.0029). Similarly, mean CS and HVF were significantly more impaired in REVERSE vs RESCUE subjects (P < 0.005). The cross-sectional analysis showed that the monthly decrease in BCVA, ganglion cell layer macular volume, and retinal nerve fiber layer thickness was much more pronounced in the first 6 months after onset (+0.24 LogMAR, −0.06 mm 3, and −6.00 μm respectively) than between 6 and 12 months after onset (+0.02 LogMAR, −0.01 mm 3, and −0.43 μm respectively). Conclusion: LHON progresses rapidly in the first months following onset during the subacute phase, followed by relative stabilization during the dynamic phase.

Overview

CoChat Summary

TL;DR

This cross-sectional baseline analysis of the RESCUE and REVERSE phase III gene therapy trials describes visual function and retinal anatomy in 76 subjects with m.11778G>A LHON during the first year after vision loss. Functional and structural parameters worsened most rapidly in the first 6–8 months after onset, then relatively stabilized.

Key findings

  • Among 76 subjects (39 RESCUE, 37 REVERSE), mean duration of vision loss was 112.1 days in RESCUE vs 271.0 days in REVERSE (P < 0.0001). Baseline BCVA was worse in REVERSE than RESCUE (1.61 vs 1.29 LogMAR, P = 0.0029), as were contrast sensitivity (0.30 vs 0.62 LogCS, P = 0.0031) and HVF mean deviation (−29.0 vs −19.9 dB, P = 0.0039).
  • Structural loss was also more advanced in REVERSE: GCL macular volume 0.53 vs 0.73 mm³, RNFL temporal quadrant 28.2 vs 49.6 μm, and average RNFL 69.7 vs 99.1 μm (all P < 0.0001).
  • Estimated monthly rates in the first 6 months after onset were +0.24 LogMAR for BCVA, −0.06 mm³ for GCL macular volume, and −6.00 μm for RNFL temporal quadrant thickness; between 6 and 12 months, the corresponding rates were +0.02 LogMAR, −0.01 mm³, and −0.43 μm.
  • Four RESCUE eyes had normal BCVA at enrollment but already showed contrast sensitivity below 1.8 LogCS and presymptomatic increases in retinal layer thickness/volume.

Methods

  • Cross-sectional analysis of baseline data from RESCUE (NCT02652767) and REVERSE (NCT02652780), two randomized, double-masked, sham-controlled phase III trials of rAAV2/2-ND4 in subjects with m.11778G>A LHON; RESCUE enrolled vision loss ≤180 days and REVERSE 181–365 days, with subjects at least 15 years old and vision of count fingers or better in both eyes.
  • Functional measures included ETDRS BCVA, Pelli–Robson contrast sensitivity, and Humphrey Visual Field 30-2; structural measures included SD-OCT GCL and RNFL parameters. Functional baseline was the last pre-treatment assessment; OCT baseline averaged screening and inclusion visits.
  • Analyses used mixed-effects ANOVA for dependent data, linear regression on individual data points to estimate monthly rates of change, and LOESS nonparametric regression; SAS version 9.4 was used.

Limitations

  • Stated: the analysis is cross-sectional, subjects were subsequently treated with gene therapy and not followed longitudinally as untreated individuals, so the reconstruction of natural history is not based on prospective follow-up of individual patients. Also stated: only reliable HVF tests were included, excluding more than half of the data; whole mitochondrial genome sequencing was not performed and nuclear genome sequencing was not specifically requested to exclude other optic atrophy genes; onset of vision loss was based on patient testimony.
  • Evident from the text: the two cohorts differ by design in duration of vision loss, so baseline comparisons between RESCUE and REVERSE are confounded by disease stage. The cross-sectional design cannot establish individual trajectories or causality, and the absence of an untreated longitudinal control limits natural-history inference.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1097/wno.0000000000001316

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

FIG. 1. Visual function parameters up to one year after onset of vision loss in subjects with LHON harboring the m.11778G>A mutation. N: number of observations pooled together to calculate the means. Individual values were collected at screening and inclusion, then grouped and averaged by time since onset of vision loss. Because of a very low number of observations available before onset of vision loss, no standard error was calculated. A. Best-corrected visual acuity, B. contrast sensitivity, C. HVF mean deviation. HVF, Humphrey Visual Field; LHON, Leber hereditary optic neuropathy.
FIG. 1. Visual function parameters up to one year after onset of vision loss in subjects with LHON harboring the m.11778G>A mutation. N: number of observations pooled together to calculate the means. Individual values were collected at screening and inclusion, then grouped and averaged by time since onset of vision loss. Because of a very low number of observations available before onset of vision loss, no standard error was calculated. A. Best-corrected visual acuity, B. contrast sensitivity, C. HVF mean deviation. HVF, Humphrey Visual Field; LHON, Leber hereditary optic neuropathy.CC BY-NC-ND · PubMed Central
FIG. 2. Retinal parameters up to one year after onset of vision loss in subjects with LHON harboring the m.11778G>A mutation. N: number of observations pooled together to calculate the means. Individual values were collected at screening and inclusion, then grouped and averaged by time since onset of vision loss. Because of a very low number of observations available before onset of vision loss, no standard error was calculated. A. Ganglion cell layer macular volume, B. Retinal nerve fiber layer (RNFL) temporal quadrant thickness, C. Average RNFL thickness.
FIG. 2. Retinal parameters up to one year after onset of vision loss in subjects with LHON harboring the m.11778G>A mutation. N: number of observations pooled together to calculate the means. Individual values were collected at screening and inclusion, then grouped and averaged by time since onset of vision loss. Because of a very low number of observations available before onset of vision loss, no standard error was calculated. A. Ganglion cell layer macular volume, B. Retinal nerve fiber layer (RNFL) temporal quadrant thickness, C. Average RNFL thickness.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

0 Valid · 0 Not valid · 2 Not checked · 47 Own results and interpretations

15 more claims

Create a free account to see all 49 claims and to verify the 3 references still open.

See all claims — free account
  • Probably not a substantial claim. 15
  • It may state two separate claims as one. 16
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

5 of 6 · the rest aren’t loaded

1 more finding

Create a free account to see every finding of this check.

See all findings — free account

Citations

Cites

Show all 29 references

Cited by

See all 8

Metadata

Authors
Moster, M. L., Sergott, R. C., Newman, N. J., Yu-Wai-Man, P., Carelli, V., Bryan, M. S., Smits, G., Biousse, V., Vignal-Clermont, C., Klopstock, T., Sadun, A. A., DeBusk, A. A., Carbonelli, M., Hage, R., Priglinger, S., Karanjia, R., Blouin, L., Taiel, M., Katz, B., Sahel, J. A., & for the LHON study group
Affiliations
  • Thomas Jefferson University (US)
  • Centre National de la Recherche Scientifique (FR)
Corresponding author
Moster, Mark L.
Venue
Journal of Neuro-Ophthalmology
Published
2021-07-23
Volume
41
Issue
3
Pages
298-308
ISSN
1070-8022 (ISSN-L)
OpenAlex
W3183408771
Cited by
7
References
30
Citations by year
2026: 1 · 2025: 1 · 2022: 5
FWCI
1.12
Type
journal article
Language
en
Open access
Locations
  • Journal of Neuro-Ophthalmology (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • The Medicine Forum (submittedVersion, cc-by-nc-nd)
  • Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, cc-by-nc-nd)
  • Open access LMU (Ludwid Maxmilian's Universitat Munchen) (submittedVersion)
  • eScholarship (California Digital Library) (submittedVersion, cc-by-nc-nd)
  • DZNE Pub (submittedVersion)
Funders
  • E-Rare
  • National Institute for Health and Care Research (G1002570)
  • Sight Research UK (SEE 003)
  • Agence Nationale de la Recherche (ANR‐10‐LABX‐65, ANR18, 10-LABX-65, ANR-18-IAHU-0001, ANR-10)
  • Bundesministerium für Bildung und Forschung (01GM1920B, 01GM1906A)
  • Ministero della Salute (2018-, RF-2018-12366703, RF-2018)
  • Isaac Newton Trust (G1002570)
  • Moorfields Eye Hospital NHS Foundation Trust
  • Moorfields Eye Charity
  • National Institutes of Health (-0001, EY006360)
  • Medical Research Council (G1002570)
  • National Eye Institute (EY 006360, P30EY006360)
Topics
  • Health Sciences › Medicine › Ophthalmology › Glaucoma and retinal disorders
  • Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
Keywords
Leber's hereditary optic neuropathy, REVERSE trial, best-corrected visual acuity, contrast sensitivity, visual field, retinal nerve fiber layer thickness, disease progression, subacute phase
MeSH terms
Adolescent, Adult, Aged, Cross-Sectional Studies, DNA, Mitochondrial, Double-Blind Method, Female, Humans, Male, Middle Aged, Retinal Ganglion Cells, Visual Acuity, Visual Fields, Genetic Therapy, Optic Atrophy, Hereditary, Leber, Tomography, Optical Coherence, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cross-Sectional Analysis of Baseline Visual Parameters in Subjects Recruited Into the RESCUE and REVERSE ND4-LHON Gene Therapy Studies. https://app.cochat.ai/papers/10.1097/wno.0000000000001316
The paper
Moster, M. L., Sergott, R. C., Newman, N. J., Yu-Wai-Man, P., Carelli, V., Bryan, M. S., Smits, G., Biousse, V., Vignal-Clermont, C., Klopstock, T., Sadun, A. A., DeBusk, A. A., Carbonelli, M., Hage, R., Priglinger, S., Karanjia, R., Blouin, L., Taiel, M., Katz, B., . . . for the LHON study group. (2021). Cross-Sectional Analysis of Baseline Visual Parameters in Subjects Recruited Into the RESCUE and REVERSE ND4-LHON Gene Therapy Studies. Journal of Neuro-Ophthalmology. https://doi.org/10.1097/wno.0000000000001316

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.